Tengsheng Pharma was selected to be included in the MSCI China small cap index.

The MSCI China small cap index is a stock index compiled by Mingsheng, a leading supplier of key decision support tools and services to the global investment community. The index, which aims to measure the performance of small-cap stocks in the Chinese market, is widely recognized by China Finance Online Co Ltd and is a benchmark for global institutional investors seeking to optimize their portfolios.

Tengsheng Bo Pharmaceuticals was selected for inclusion in the semiannual index review of the MSCI stock index in May 2022.

Becoming a member of the MSCI China small cap index is another important milestone in the capital market after we were included in the Hang Seng Composite Index and the Shenzhen-Hong Kong Stock Connect last year. As one of the few biotech stocks that have been included in one of the most influential China-focused indices in global capital markets, it shows that our visibility and the recognition of global investors are growing. We look forward to continuing to create value for shareholders by developing innovative treatments for diseases with significant unmet medical needs and a huge public health burden around the world.

Tengsheng Boyao Biotechnology Co., Ltd. ("Tengsheng Boyao" 2137.HK) is a biotech company based in China and the United States. It is committed to developing innovative treatments for major infectious diseases in China and around the world, such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multiple drug resistance (MDR) or extensively drug resistance (XDR) gram-negative bacteria infection, and other diseases with significant public health burden, such as central nervous system (CNS) diseases.